Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the overall best tumor response rate to dacarbazine
given until disease progression as assessed by RECIST criteria, CT and clinical exams in
patients with metastatic sarcomas.